Skip to main content
. 2019 Sep;370(3):823–833. doi: 10.1124/jpet.119.257345

Fig. 6.

Fig. 6.

Effect of δ-tocopherol on the activity provided by recombinant ASM to diseased cells. (A) ASM activity in wild-type (Ctrl) or NPD-A patient fibroblasts (Dis) incubated for 4 hours in the absence vs. presence of 2.3 µg/ml recombinant ASM. (B) ASM activity in healthy (Ctrl) vs. imipramine-diseased endothelial cells or NPD-A fibroblasts (Dis) after incubation for 4 hours with 2.3 µg/ml recombinant ASM, which was added after treatment with 40 µM δ-tocopherol. Data are normalized to (A) wild-type fibroblasts without ASM addition and to (B) untreated cells (respective horizontal dashed lines). (C) NPD-A fibroblasts treated for 48 hours with 40 µM δ-tocopherol and labeled with fluorescent sphingomyelin were washed and incubated with 5 µg/ml recombinant ASM for 4 hours, after which the sphingomyelin levels were measured in a plate reader. Data show sphingomyelin levels as a percentage of that found in cells not incubated with ASM. All data are mean ± S.E.M. (n ≥ 4 independent wells). (A and B) *Comparison with wild-type fibroblasts without ASM addition; †comparison with untreated cells; (C) *comparison with untreated cells (all P < 0.05 by Student’s t test).